P-7600 PKC412, >99%

Related Terms : [CGP41251] [4'-N-Benzoyl Staurosporine] [Midostaurin]

Prices_reduced
  • Size
  • US $
  • £
  • ¥
  • 1 mg
  • 47
  • 42
  • 35
  • 4,800
  • Add to Cart Qty:
  • In stock
  • 5 mg
  • 124
  • 110
  • 93
  • 12,700
  • Add to Cart Qty:
  • In stock
  • 10 mg
  • 199
  • 178
  • 150
  • 20,300
  • Add to Cart Qty:
  • In stock
  • 25 mg
  • 390
  • 349
  • 294
  • 39,800
  • Add to Cart Qty:
  • In stock
  • 50 mg
  • 541
  • 484
  • 408
  • 55,200
  • Add to Cart Qty:
  • In stock
  • 100 mg
  • 968
  • 866
  • 731
  • 98,800
  • Add to Cart Qty:
  • In stock
  • 200 mg
  • 1,630
  • 1,458
  • 1,232
  • 166,400
  • Add to Cart Qty:
  • In stock

Note: Our Euro, Pound, and Yen prices are revised regularly to account for currency exchange rate fluctuations.

To receive a Quotation for catalog sizes of this product and/or any other products, please add them to your shopping cart and click on the “REQUEST A QUOTATION” box.
Click Here to Request a Quotation for Larger Quantities Click Here to see what Shipping and Handling Costs would be to Your Country
  • M.W. 570.64
  • C35H30N4O4
  • [120685-11-2]
  • M.I. 14: 6185

Storage: Store at or below -20 ºC. Solubility: Soluble in DMSO at 100 mg/mL; soluble in ethanol at 5 mg/mL with warming; very poorly soluble in water; maximum solubility in plain water is estimated to be about 10-20 µM; buffers, serum, or other additives may increase or decrease the aqueous solubility. Disposal: A.

  • The staurosporine analog, PKC412, inhibits a variety of serine/threonine and tyrosine kinases including PKC (IC50 = 50 nM), cyclic AMP-dependent protein kinase (IC50 = 2.4 µM), S6 kinase (IC50 = 5.0 µM), and EGFR (epidermal growth factor receptor) tyrosine-kinase activity (IC50 = 3.0 µM). Meyer, T., et al. "A derivative of staurosporine (CGP 41 251) shows selectivity for protein kinase C inhibition and in vitro anti-proliferative as well as in vivo anti-tumor activity." Int. J. Cancer 43: 851-856 (1989).
  • PKC412 inhibits autophosphorylation of platelet-derived growth factor (PDGF) receptor in BALB/c 3T3 cells at submicromolar concentrations. Andrejauskas-Buchdunger, E. and Regenass, U. "Differential inhibition of the epidermal growth factor-, platelet-derived growth factor-, and protein kinase C-mediated signal transduction pathways by the staurosporine derivative CGP 41251." Cancer Research, 52: 5353-5358 (1992).
  • PKC412 strongly blocks the proliferation of ras-transformed pancreatic cancer cells (TUC-3) by causing apoptosis and induction of phenotypic reversion. Way, D., et al. "A protein kinase C inhibitor induces phenotypic reversion of ras-transformed pancreatic cancer cells and cooperatively blocks tumor cell proliferation with an anti-ras peptide." Cancer Chemother. Pharmacol. 49: 429-437 (2002).
  • PKC412 suppresses Akt activity by blocking serine phosphorylation in the kinase activation loop and induces apoptosis in myeloma cell lines. Bahlis, N.J., et al. "N-Benzoylstaurosporine (PKC412) inhibits Akt kinase inducing apoptosis in multiple myeloma cells." Leuk. Lymphoma 46: 899-908 (2005).
  • PKC412 selectively inhibits T lymphocyte production of TNF-α (tumor necrosis factor - alpha) with an IC50 of 0.5 µM. Si, M.S., et al. "Effects of the kinase inhibitor CGP41251 (PKC 412) on lymphocyte activation and TNF-alpha production." Int. Immunopharmacol. 5: 1141-11419 (2005).
  • Not available in some countries; not available to some institutions; may not be sold for some uses.
  • Sold for laboratory or manufacturing purposes only; not for human, medical, veterinary, food, or household use.
249